Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2018

01-01-2018

Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia

Authors: Ming Y. Lim, Joyce Foster, Angela Rourk, Charles S. Greenberg

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2018

Login to get access

Abstract

Many medical centers are faced with a major challenge in making an accurate diagnosis of heparin-induced thrombocytopenia (HIT) and ensuring appropriate changes in management strategy in line with guideline recommendations. We report the initial and long-term impact and challenges of institution-wide changes in the diagnosis and management of HIT in the inpatient setting at an academic medical center. We established a HIT Task Force, consisting of a multidisciplinary team of non-malignant hematologists, nursing, pharmacist, pathology, blood bank and clinical lab informatics. Changes were implemented from 2011 to 2012. In 2013, testing for PF4 and SRA decreased by 37.5 and 85%, respectively. 100% of positive PF4 received an automatic hematology consult to guide management, leading to a 78% reduction in the use of direct thrombin inhibitors. Annual audits in the subsequent years demonstrated increasing testing for HIT due to changes in the electronic ordering system. Through continuous monitoring, these shortfalls were detected and intervene early on with continued success. The implementation of a centralized hospital-wide protocol via a multidisciplinary task force that coordinates testing and treatment of patients suspected of having HIT led to a substantial reduction in PF4 and SRA testing, as well as use of DTIs, resulting in a safe and cost-effective approach for the diagnosis and treatment of HIT. Our study highlights the important of continuous monitoring to maintain the improvements made. Despite our initial success, annual re-auditing allowed for early detection of challenges, which then allowed appropriate early intervention.
Literature
2.
go back to reference Kelton JG, Arnold DM, Bates SM (2013) Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 368:737–744CrossRefPubMed Kelton JG, Arnold DM, Bates SM (2013) Nonheparin anticoagulants for heparin-induced thrombocytopenia. N Engl J Med 368:737–744CrossRefPubMed
3.
go back to reference Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037–1043CrossRefPubMed Lo GK, Sigouin CS, Warkentin TE (2007) What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 82:1037–1043CrossRefPubMed
4.
go back to reference Warkentin TE, Sheppard JI, Moore JC, Kelton JG (2010) The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 8:216–218CrossRefPubMed Warkentin TE, Sheppard JI, Moore JC, Kelton JG (2010) The use of well-characterized sera for the assessment of new diagnostic enzyme-immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 8:216–218CrossRefPubMed
5.
go back to reference Burnett AE, Bowles H, Borrego ME, Montoya TN, Garcia DA, Mahan C (2016) Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory. J Thromb Thrombolysis 42:471–478CrossRefPubMed Burnett AE, Bowles H, Borrego ME, Montoya TN, Garcia DA, Mahan C (2016) Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory. J Thromb Thrombolysis 42:471–478CrossRefPubMed
6.
go back to reference Hasan M, Malalur P, Agastya M et al (2016) A high-value cost conscious approach to minimize heparin induced thrombocytopenia antibody (HITAb) testing using the 4T score. J Thromb Thrombolysis 42:441–446CrossRefPubMed Hasan M, Malalur P, Agastya M et al (2016) A high-value cost conscious approach to minimize heparin induced thrombocytopenia antibody (HITAb) testing using the 4T score. J Thromb Thrombolysis 42:441–446CrossRefPubMed
7.
go back to reference Ritchie BM, Sylvester KW, Reardon DP, Churchill WW, Berliner N, Connors JM (2016) Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. J Thromb Thrombolysis 42:616–622CrossRefPubMed Ritchie BM, Sylvester KW, Reardon DP, Churchill WW, Berliner N, Connors JM (2016) Treatment of heparin-induced thrombocytopenia before and after the implementation of a hemostatic and antithrombotic stewardship program. J Thromb Thrombolysis 42:616–622CrossRefPubMed
8.
go back to reference Wychowski MK, Ruscio CI, Kouides PA, Sham RL (2017) The scope and value of an anticoagulation stewardship program at a community teaching hospital. J Thromb Thrombolysis 43:380–386CrossRefPubMed Wychowski MK, Ruscio CI, Kouides PA, Sham RL (2017) The scope and value of an anticoagulation stewardship program at a community teaching hospital. J Thromb Thrombolysis 43:380–386CrossRefPubMed
9.
go back to reference Linkins LA, Dans AL, Moores LK et al (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e495S-e530SCrossRefPubMedPubMedCentral Linkins LA, Dans AL, Moores LK et al (2012) Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 141:e495S-e530SCrossRefPubMedPubMedCentral
10.
go back to reference Pierce W, Mazur J, Greenberg C, Mueller J, Foster J, Lazarchick J (2013) Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit. Ann Clin Lab Sci 43:429–435PubMed Pierce W, Mazur J, Greenberg C, Mueller J, Foster J, Lazarchick J (2013) Evaluation of heparin-induced thrombocytopenia (HIT) laboratory testing and the 4Ts scoring system in the intensive care unit. Ann Clin Lab Sci 43:429–435PubMed
11.
go back to reference Samuelson BT, Glynn E, Holmes M, White AA, Martin DB, Garcia D (2015) Use of a computer-based provider order entry (CPOE) intervention to optimize laboratory testing in patients with suspected heparin-induced thrombocytopenia. Thromb Res 136:928–931CrossRefPubMed Samuelson BT, Glynn E, Holmes M, White AA, Martin DB, Garcia D (2015) Use of a computer-based provider order entry (CPOE) intervention to optimize laboratory testing in patients with suspected heparin-induced thrombocytopenia. Thromb Res 136:928–931CrossRefPubMed
Metadata
Title
Initial and long term impact of a multi-disciplinary task force in the diagnosis and management of heparin-induced thrombocytopenia
Authors
Ming Y. Lim
Joyce Foster
Angela Rourk
Charles S. Greenberg
Publication date
01-01-2018
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2018
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-017-1592-z

Other articles of this Issue 1/2018

Journal of Thrombosis and Thrombolysis 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.